Join us June 14-18, 2026
in Philadelphia, PA
Join global leaders, innovators, regulators, academics, and patient advocates in Philadelphia, PA for the DIA 2026 Global Annual Meeting. As the life sciences industry continues to evolve, this event serves as a powerful platform to connect, collaborate, and drive forward transformative solutions. Be part of the conversations shaping tomorrow—right in the heart of one of America’s most historic and inspiring cities.
Conference Highlights
Interactive sessions, keynote presentations, and hands-on workshops designed to accelerate your professional growth and expand your network.
Announcements and Highlights
-
About
DIA 2026 is more than a meeting—it’s a movement shaping the future of health.
Learn More -
Registration is Open!
Don’t miss your chance to secure your spot.
Register Today! -
Call for Posters
The Call for Professional and Student Posters is Open!
Learn More -
Hotels are Open!
Book your stay at an official DIA Hotel!
Book Today! -
Social
Follow us on Twitter, Facebook, and LinkedIn @DrugInfoAssn and #DIA2026 for continuous updates!
Follow Us -
Exhibits & Sponsorship!
Secure Your Space Today and Make a Lasting Impression!
Learn More!
Reach out to SB Expos & Events at DIAsales@discoversb.com for more information.
Comité del programa
-
Representative Invited • FDA, United States
-
Sanghita Bhattacharya, PhD • Director Data Science Global Function
Johnson & Johnson Innovative Medicine, United States -
Asia Blackwell • Consumer Safety Officer, CBER
FDA, United States -
Tywnia Brewton • Executive Director, Human Resources
Astellas , United States -
James Buchanan, PharmD • President
Covilance LLC, United States -
Mandy Kaur Budwal-Jagait, MSc • Head of GCP
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Meghana Chalasani, MHA • Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
FDA, United States -
Joan Chambers • Independent Senior Consultant
Tufts Center For the Study of Drug Development, United States -
Rachel Chasse, MS • Associate Director, Digital Science Strategy
AbbVie, United States -
Monica Chiaramonte, PhD • Director, Clinical Regulatory Writing
AstraZeneca Pharmaceuticals LP, United States -
Christine Colvis, PhD • Director, Drug Development Partnership Programs
National Center for Advancing Translational Sciences (NCATS), United States -
Karen Correa, PhD • Vice President, Clinical Development Operations
Boehringer Ingelheim, United States -
Solange Corriol-Rohou, DrMed, MD, PhD •
SCR Consulting, France -
Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy
University of Illinois at Chicago, United States -
Alysha Croker, PhD • Director, Strategic and Horizontal Policy
Health Canada, Canada -
Matthew Curin, PharmD • Sr. Dir, Head of Program Management, Therapeutic Dermatology
Galderma, United States -
Representative Invited • FDA, United States
-
Victoria DiBiaso, BSN, MPH, RN • Global Head, Patient Informed Development and Health Value Translation
Sanofi, France -
Megan Doyle, JD, MPH • Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States -
Nancy Dreyer, PhD, MPH, FISPE • Founder
Dreyer Strategies LLC, United States -
Joseph Dustin • Founder and Principal
Dauntless Eclinical Strategies, United States -
Jennifer Emerson, PhD, MPH, RN, PMP • Head Quality Analytics & Risk Management
Boehringer Ingelheim, Germany -
Andrew Emmett, MPH • VP, Global Regulatory Policy and Global Intelligence
Pfizer Inc, United States -
Celeste Frankenfeld Lamm • Senior Director, Global Regulatory Affairs – CMC
Merck Sharp & Dohme LLC , United States -
Danielle Friend Economo, PhD • Senior Director, US Head Regulatory Policy and Intelligence
Johnson & Johnson Innovative Medicine, United States -
David Fryrear, MS • Chief Quality Officer
Astellas, United States -
Cheryl Grandinetti, PharmD • Associate Director for Clinical Policy, CDER/OC/OSI/DCCE
FDA, United States -
Courtney Granville, PhD, MPH •
United States -
Lani Hashimoto • Consultant, Patient Experience
Hashimoto Consulting Services, United States -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Cammilla Horta Gomes, MA, MPharm • Latam Regulatory Policy Lead
Roche, Brazil -
Stacy Hurt, MBA, MHA • Chief Patient Officer
Parexel, United States -
Huong Huynh, PhD • Director of Regulatory Science
Critical Path Institute, United States -
Yatika Kohli, PhD, MBA • Chief Compliance and Strategy Officer
NoNO Inc, Canada -
Dominique Lagrave, PharmD • Chief Regulatory Officer
Accumulus Technologies, United States -
Elizabeth Lange, MPH, MS • Executive Director/ Head of Regulatory Scientific Policy
EMD Serono, United States -
Jingyu (Julia) Luan, PhD • Executive Regulatory Science Director, BioPharmaceuticals R&D
AstraZeneca, United States -
Demetra Macheras, MBA • Director, Regulatory Policy and Intelligence - Regulatory Affairs
AbbVie, United States -
David Meats • Director, Regulatory Services & Medical Affairs Management
Certara, United States -
Timothe Menard, PharmD, MSc • Global Head, Quality Excellence Digital | Bioethics Ambassador
F. Hoffmann-La Roche Ltd, Switzerland -
Pallavi Mishra-Kalyani, PhD, MS • Deputy Division Director, DBV, OB, CDER
FDA, United States -
May F Mo, MBA, MS • Executive Director, Biostatistics
Amgen, United States -
Monica Munoz, PharmD, PhD • Division Director, Division of Pharmacovigilance-I, OSE, CDER
FDA, United States -
Lauren Oliva, PharmD, RPh • US Regulatory Policy Lead
Biogen, United States -
Representative Invited • FDA, United States
-
Vada Perkins, DrSc, MSc • Vice President, Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim, United States -
Regina Lynn Preciado • VP, Content Strategy Solutions
Content Rules, Inc., United States -
Ranjini Prithviraj, PhD, PMP • Director, Global Medical Affairs, Publication Management
Regeneron, United States -
Kim Ribeiro, MS • Director Patient Experience & Engagement
Boehringer Ingelheim, United States -
Leslie Sam • President
Leslie Sam and Associates, LLC, United States -
Earl Seltzer, MBA • Senior Director, Partnerships and Innovation
CTI, United States -
Anjali Shah, PharmD • Executive Director, Business Capabilities and Innovation, WWPS
Bristol-Myers Squibb Company, United States -
Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences
University of Southern California School of Pharmacy, United States -
Cary Smithson, MBA • Managing Partner
LeapAhead Solutions, Inc., United States -
Benjamin Stevens, PhD, MPH • Director CMC Policy and Advocacy
GlaxoSmithKline, United States -
Nancy Linda Styple • Project Management Leader
Bayer AG, United States -
Ling Su, PhD • Research Fellow
Yeehong Business School, China -
John Z. Sun, PhD, MBA, PMP • Program Lead, Global Clinical Operation, Development
Novartis Pharmaceuticals Corporation, United States -
Michael Torok, PhD • Vice President, Global Head of Quality Assurance Programs
Genentech, A Member of the Roche Group, United States -
Phil Tregunno • Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Representative Invited • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
James Valentine, JD, MHS • Director
Hyman, Phelps & McNamara, PC, United States -
James Wabby, MHS • Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States -
Paula Walker, MA • Global Head of Risk Based Quality Management
Roche Products Ltd., United Kingdom -
Robin Whitsell • President
Whitsell Innovations, Inc., United States -
Amira Deia Younes • Director-Eastern Europe, Middle East & Africa (EEMEA) Global Regulatory Policy
MSD, United Arab Emirates
